For cytotoxic drugs, the incidence of AE was traditionally reported as frequency and intensity. This simple measure is not sufficient to summarize AE for MTT. Prevalence permits to obtain a time profile of AE and Q-TWiST assesses the "risk-benefit" ratio of a treatment. These methods are helpful for physicians in their treatment choice, to counsel patients and to optimize supportive care .
from Cancer via ola Kala on Inoreader http://ift.tt/1NIqdiI
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου